image
Healthcare - Biotechnology - NASDAQ - US
$ 0.8226
2.09 %
$ 13 M
Market Cap
-1.08
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ABVC stock under the worst case scenario is HIDDEN Compared to the current market price of 0.823 USD, ABVC BioPharma, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ABVC stock under the base case scenario is HIDDEN Compared to the current market price of 0.823 USD, ABVC BioPharma, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ABVC stock under the best case scenario is HIDDEN Compared to the current market price of 0.823 USD, ABVC BioPharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ABVC

image
$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
509 K REVENUE
233.81%
48.5 K OPERATING INCOME
100.59%
-5.37 M NET INCOME
100.00%
0 OPERATING CASH FLOW
100.00%
0 INVESTING CASH FLOW
100.00%
1.98 M FINANCING CASH FLOW
-49.46%
389 K REVENUE
232.31%
49.9 K OPERATING INCOME
105.11%
-187 K NET INCOME
81.58%
172 K OPERATING CASH FLOW
116.93%
0 INVESTING CASH FLOW
0.00%
-145 K FINANCING CASH FLOW
-16.74%
Balance Sheet ABVC BioPharma, Inc.
image
Current Assets 2.18 M
Cash & Short-Term Investments 313 K
Receivables 0
Other Current Assets 1.87 M
Non-Current Assets 5.36 M
Long-Term Investments 2.26 M
PP&E 1.15 M
Other Non-Current Assets 1.95 M
4.15 %24.76 %29.96 %15.27 %25.86 %Total Assets$7.5m
Current Liabilities 6.56 M
Accounts Payable 0
Short-Term Debt 2.19 M
Other Current Liabilities 4.36 M
Non-Current Liabilities 258 K
Long-Term Debt 237 K
Other Non-Current Liabilities 21.7 K
32.19 %64.02 %3.47 %Total Liabilities$6.8m
EFFICIENCY
Earnings Waterfall ABVC BioPharma, Inc.
image
Revenue 509 K
Cost Of Revenue 0
Gross Profit 509 K
Operating Expenses 2.44 M
Operating Income 48.5 K
Other Expenses 5.42 M
Net Income -5.37 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)509k0509k(2m)48k(5m)(5m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
9.53% OPERATING MARGIN
9.53%
-1055.29% NET MARGIN
-1055.29%
-437.93% ROE
-437.93%
-71.22% ROA
-71.22%
1.53% ROIC
1.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ABVC BioPharma, Inc.
image
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.37 M
Depreciation & Amortization 6.24 M
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 0
Others 0
Free Cash Flow 0
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ABVC BioPharma, Inc.
image
ABVC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership ABVC BioPharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. ("OncoX") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.1 globenewswire.com - 4 months ago
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches. globenewswire.com - 6 months ago
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements • Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) --   ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1. globenewswire.com - 8 months ago
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life. globenewswire.com - 1 year ago
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. We are hopeful that this agreement will facilitate the advancement of treatments for Non-Small Cell Lung Cancer (NSCLC) since it covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer. ABVC and its affiliate are set to receive an aggregate license fee of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional milestone payment of $1,250,000 in cash after OncoX's next round of fundraising, of which there can be no guarantee; ABVC and its affiliate are also entitled to royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product. globenewswire.com - 1 year ago
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire --  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products. globenewswire.com - 1 year ago
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. globenewswire.com - 1 year ago
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire --  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by  CEO Insights Asia Magazine . This recognition is a testament to Dr. Patil's outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary. Within his first year as the Company's CEO, the Company saw a rise in the stock price of its common stock, an increase in its social media presence, and a renewed focus on its essential products. globenewswire.com - 1 year ago
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024. globenewswire.com - 1 year ago
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expertise ("Know-How") to Senior Paradise, Inc. ("SPI"), who will also lease certain of the Company's properties (the "Land") for further development related to the healthcare industry. The lease, SPI may build a long-term care center for the elderly, plant factories, and good agricultural practices (GAP) for botanical drug products and dietary supplements. globenewswire.com - 1 year ago
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire –  ABVC BioPharma, Inc.  (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD). globenewswire.com - 1 year ago
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries. globenewswire.com - 1 year ago
8. Profile Summary

ABVC BioPharma, Inc. ABVC

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 13 M
Dividend Yield 0.00%
Description ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Contact 44370 Old Warm Springs Boulevard, Fremont, CA, 94538 https://www.abvcpharma.com
IPO Date Nov. 10, 2004
Employees 16
Officers Mr. Eugene Jiang Chairman & Chief Business Officer Dr. Tsung-Shann Jiang EMBA, Ph.D. Chief Scientific Officer, Chief Strategy Officer & Director Dr. Uttam Yashwant Patil Ph.D. Chief Executive Officer & Interim Chief Financial Officer